Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 13/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 9/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.38 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201794 | 1.00 | GRIK1 (0.47) | GRIK1GRIK2TDP1GRM1GRM2 | |
| Hydrochloric Acid SCHEMBL29425835 | 0.98 | GRIK1 (0.46) | GRIK1GRIK2TDP1GRM1GRM2 | |
| SCHEMBL2402182 | 0.87 | GRIK1 (0.44) | GRIK1GRIK2TDP1GRM1GRM2 | |
| SCHEMBL176160 | 0.86 | TDP1 (0.46) | GRIK1GRIK2TDP1TSHRPKM | |
| SCHEMBL1023364 | 0.86 | TDP1 (0.46) | GRIK1GRIK2TDP1TSHRPKM | |
| SCHEMBL30394373 | 0.86 | GRIK1 (0.42) | GRIK1GRIK2TDP1GRM1GRM2 | |
| SCHEMBL176228 | 0.81 | GRIK1 (0.48) | GRIK1GRIK2TDP1GRM1GRM2 | |
| SCHEMBL666790 | 0.81 | GRIK1 (0.48) | GRIK1GRIK2TDP1GRM1GRM2 | |
| SCHEMBL7198969 | 0.81 | GRIK1 (0.52) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL3788767 | 0.80 | GRIK1 (0.47) | GRIK1GRIK2GRM1GRM2GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107597075-A | A kind of preparation method of Chinese gooseberry beverage adsorbent | 江山海维科技有限公司 | 2018-01-19 | — | — | CN | claimed |
| US-12466894-B2 | Anti-MUC16 antibodies and uses thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4077353-B1 | SYNTHESIS OF AMANIN AND ITS DERIVATIVES | HEIDELBERG PHARMA RES GMBH (DE) | 2025-04-23 | — | — | EP | disclosed |
| EP-4190817-A1 | ANTI-MUC16 ANTIBODIES AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230039142-A1 | SYNTHESIS OF AMANIN AND ITS DERIVATIVES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-02-09 | — | — | US | disclosed |
| US-20230026100-A1 | ANTI-MUC16 ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3271398-B1 | ANTI-MUC16 ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021014380-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2021-01-28 | — | — | WO | disclosed |
| CN-107597075-A | A kind of preparation method of Chinese gooseberry beverage adsorbent | 江山海维科技有限公司 | 2018-01-19 | — | — | CN | disclosed |
| US-7989216-B2 | Polypeptide comprising staphylococcal protein a/b domains for use as fusion components for directing immunoglobulins to preferential targets; specifically binds to human epidermal growth factor receptor 2 (HER2) | GENERAL ELECTRIC COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100041073-A1 | TWO HELIX BINDERS | GENERAL ELECTRIC COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041073-A1 | TWO HELIX BINDERS | GENERAL ELECTRIC COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041073-A1 | TWO HELIX BINDERS | GENERAL ELECTRIC COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100035361-A1 | TWO HELIX BINDERS | GENERAL ELECTRIC COMPANY (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100035361-A1 | TWO HELIX BINDERS | GENERAL ELECTRIC COMPANY (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100035361-A1 | TWO HELIX BINDERS | GENERAL ELECTRIC COMPANY (US) | 2010-02-11 | — | — | US | disclosed |
| US-20090325313-A1 | TWO HELIX BINDERS | GENERAL ELECTRIC COMPANY (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325313-A1 | TWO HELIX BINDERS | GENERAL ELECTRIC COMPANY (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325313-A1 | TWO HELIX BINDERS | GENERAL ELECTRIC COMPANY (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325313-A1 | TWO HELIX BINDERS | CNBP, AEBP2, CRYAB | GRIK1 4566/4885GRIK2 4334/4885TDP1 3857/4885 |
| US-20230039142-A1 | SYNTHESIS OF AMANIN AND ITS DERIVATIVES | AANAT, TYR, CIAPIN1 | GRIK1 4141/4885GRIK2 3867/4885TDP1 3871/4885 |
| US-20100035361-A1 | TWO HELIX BINDERS | CRYAB, AEBP2, CNBP | GRIK1 4608/4885GRIK2 4379/4885TDP1 4397/4885 |
| US-20100041073-A1 | TWO HELIX BINDERS | CRYAB, CNBP, AEBP2 | GRIK1 4577/4885GRIK2 4405/4885TDP1 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.